Opens in a new tab

Breaking news

Microsoft Ceases Cloud Services to Israeli Defense Division Amid Ethical Scrutiny

Microsoft has announced a decisive move to halt specific cloud services provided to a division within the Israeli Ministry of Defense. This measure follows emerging evidence supporting claims by The Guardian that elements of Israel’s surveillance practices may have leveraged Microsoft’s technology, particularly relating to Azure storage capacity in the Netherlands and the use of artificial intelligence services.

Strategic Decision Under Ethical Scrutiny

In a statement communicated via email, Microsoft President Brad Smith confirmed that the company’s internal review has validated aspects of the report regarding the Israeli Defense Forces’ Unit 8200. This move underscores the company’s commitment to aligning its technological offerings with its ethical standards, even as pressures mount from within its own ranks.

Investigative Findings and Operational Implications

Microsoft’s decision comes on the heels of a report indicating that Unit 8200 may have developed systems to monitor Palestinians’ phone calls. While the specifics of the services discontinued were not disclosed, Smith noted that evidence related to the consumption of Azure storage and the use of AI functionalities was particularly compelling. This proactive step highlights the growing importance of ethical considerations in the deployment of advanced technologies in sensitive international contexts.

Internal Dissent and Corporate Accountability

The decision has been accompanied by notable internal dissent. In recent weeks, Microsoft faced employee protests over the company’s involvement in providing software used during contentious military activities. The discontent culminated in the dismissal of five protesting employees, a move that reflects the turbulent balance between corporate strategy and employee-led accountability.

Geopolitical Ramifications and Industry Response

This development emerges amid heightened scrutiny of Israel’s actions in Gaza, with a United Nations commission recently alleging genocidal practices in the region. As global opinion intensifies, Microsoft’s actions not only signal a pivot in its corporate policy but also illustrate the broader industry challenge of reconciling technological innovation with ethical responsibility. Notably, as the Israeli military reportedly looked to migrate its operations to Amazon Web Services, the competitive dynamics among leading global tech firms come into sharp focus.

By acting decisively in the face of ethical dilemmas and employee demands, Microsoft is setting a precedent for how technology companies might navigate the fraught intersection of innovation, geopolitical conflict, and corporate accountability.

Blood Proteins May Signal Prostate Cancer Risk More Than 15 Years Before Diagnosis

Distinctive proteins in men’s blood may offer clues to prostate cancer risk more than 15 years before a diagnosis, according to research from the University of Oxford. The findings could help scientists better understand why some prostate cancers become aggressive while others grow slowly and never cause serious harm.

Researchers analyzed blood samples from 2,555 men collected between 1992 and 2000. Of those participants, 982 were later diagnosed with prostate cancer; the remaining 1,573 served as a comparison group. The team measured more than 6,000 proteins in the samples, which had been collected years—and, in some cases, more than 15 years—before diagnosis.

Protein Patterns Were Linked To Different Risks

The analysis identified proteins associated with prostate cancer risk overall, as well as proteins linked specifically to more aggressive or fast-growing forms of the disease. Higher levels of certain immune-system proteins, including GZMK and ANXA2, were associated with a lower long-term risk.

“Finding proteins linked to known prostate cancer driver genes in blood collected years before diagnosis gives us new insights into the earliest stages of the disease,” said Karl Smith-Byrne, the study’s corresponding author at Oxford.

The results, published in European Urology, are significant because prostate cancer is not a single, uniform disease. Many tumors grow slowly and may never threaten a patient’s health, while others progress rapidly and can be life-threatening. A clearer way to distinguish between these outcomes could eventually help improve how clinicians assess risk.

Promising Findings, Not A Screening Test

The researchers stressed that the protein patterns are not ready to be used as a screening test. The associations need further validation before they can inform clinical decisions, and the study does not establish that the proteins cause cancer or that measuring them can predict an individual’s outcome.

“Ultimately, we hope this will help us understand the biology of aggressive prostate cancer and identify markers that could improve how we assess risk in the future,” said first author Zhe Huang, a postdoctoral epidemiologist at Oxford Population Health.

Research Could Point To New Prevention Strategies

Prostate cancer is the most commonly diagnosed cancer among men in the European Union and the second most common worldwide, after lung cancer. In the EU, approximately 330,000 cases are diagnosed and 75,000 men die from the disease each year.

By identifying biological signals that appear long before diagnosis, the research may help scientists investigate the pathways involved in aggressive disease. Smith-Byrne said that, alongside existing and future genetic evidence, the findings could help reveal pathways that might ultimately be targeted to prevent aggressive prostate cancer.

Uol
Aretilaw firm
The Future Forbes Realty Global Properties
eCredo

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter